Raymond James Financial
TVTX icon

Raymond James Financial’s Travere Therapeutics TVTX Stock Holding History

Raymond James Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
+292,359
New +$13M ﹤0.01% 1701
2025
Q3 		– Sell
-2,260
Closed -$33.4K – 6659
2025
Q2 		$33.4K Buy
+2,260
New +$37.5K ﹤0.01% 5352

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's TVTX Position: Q2 2026 in Review

Raymond James Financial opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 292,359 shares worth $16.6M. The stake represents ﹤0.01% of the portfolio and ranks #1701 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in TVTX as recently as Q2 2025.

Raymond James Financial first reported a position in TVTX in Q2 2025 and has held it in 2 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Raymond James Financial held 292,359 shares of Travere Therapeutics worth $16.6M as of Q2 2026.
  • Travere Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1701 holding.
  • Raymond James Financial first reported a position in Travere Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.